Literature DB >> 34453547

Short reply to "Proton therapy for newly diagnosed glioblastoma: more room for investigation" by R. Press et al.

Caroline Chung1, Paul D Brown2, Jeffrey S Wefel1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34453547      PMCID： PMC8563305          DOI： 10.1093/neuonc/noab193

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  4 in total

1.  A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma.

Authors:  Paul D Brown; Caroline Chung; Diane D Liu; Sarah McAvoy; David Grosshans; Karine Al Feghali; Anita Mahajan; Jing Li; Susan L McGovern; Mary-Fran McAleer; Amol J Ghia; Erik P Sulman; Marta Penas-Prado; John F de Groot; Amy B Heimberger; Jihong Wang; Terri S Armstrong; Mark R Gilbert; Nandita Guha-Thakurta; Jeffrey S Wefel
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

2.  Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.

Authors:  Paul D Brown; Vinai Gondi; Stephanie Pugh; Wolfgang A Tome; Jeffrey S Wefel; Terri S Armstrong; Joseph A Bovi; Cliff Robinson; Andre Konski; Deepak Khuntia; David Grosshans; Tammie L S Benzinger; Deborah Bruner; Mark R Gilbert; David Roberge; Vijayananda Kundapur; Kiran Devisetty; Sunjay Shah; Kenneth Usuki; Bethany Marie Anderson; Baldassarre Stea; Harold Yoon; Jing Li; Nadia N Laack; Tim J Kruser; Steven J Chmura; Wenyin Shi; Snehal Deshmukh; Minesh P Mehta; Lisa A Kachnic
Journal:  J Clin Oncol       Date:  2020-02-14       Impact factor: 50.717

3.  Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma.

Authors:  S B Harrabi; N Bougatf; A Mohr; T Haberer; K Herfarth; S E Combs; J Debus; S Adeberg
Journal:  Strahlenther Onkol       Date:  2016-06-30       Impact factor: 3.621

4.  Feasibility of hippocampus-sparing VMAT for newly diagnosed glioblastoma treated by chemoradiation: pattern of failure analysis.

Authors:  Chan Woo Wee; Kyung Su Kim; Chae-Yong Kim; Jung Ho Han; Yu Jung Kim; In Ah Kim
Journal:  Radiat Oncol       Date:  2020-05-06       Impact factor: 3.481
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.